Skip to main content
Black Health logo Black Health
Dermatology Last reviewed:

Atopic Dermatitis on Black Skin

Also known as: Eczema, AD, atopic eczema

Reviewed by the Black Health editorial team Last reviewed

19.3%

of Black children in the US have atopic dermatitis vs. 16.1% of white and 7.8% of Asian children (NHANES analyses, JACI 2021)

Overview

Atopic dermatitis affects Black children at nearly double the rate of white children, yet it is consistently under-recognized and under-treated in Black patients because clinical training has long centered on how the condition looks on lighter skin.[1][2] When a doctor misreads violaceous or brown-toned inflammation as postinflammatory hyperpigmentation, the disease goes untreated -- and the window for early intervention closes. This page describes what atopic dermatitis actually looks like in Black skin, who gets it, what works, and what questions to bring to your next appointment.

How Atopic Dermatitis on Black Skin affects Black patients

The textbook picture of eczema is pink, weepy patches on flexures. That picture is built from white skin. On Black skin the inflammation reads differently and the disease often looks different at the level of the lesion itself, which is one reason recognition and treatment lag.

Color of inflammation. Erythema on darkly pigmented skin commonly appears violaceous, gray-brown, or simply as hyperpigmentation rather than red. Wilson, Alexis, and Murase (International Journal of Women's Dermatology, 2022) warn clinicians not to rely on erythema scoring alone in darker skin because severity gets underestimated.

Morphology. A papular and follicular pattern is more common in patients of African descent. Weingarten and Silverberg (JAAD, 2022) reviewed the literature on follicular eczema and found these 1 to 2 mm perifollicular papules over the trunk and extensors are characteristic of darker skin types and routinely missed when clinicians are looking for confluent flexural plaques.

Pigmentary aftermath. Atopic dermatitis is one of the leading causes of post-inflammatory hyperpigmentation in skin of color (Davis et al., reviewed in PMC9709857, 2022). These pigment changes can persist for months after the inflammation is controlled and are often what patients are most distressed about.

Severity and persistence. Black children are roughly 1.7 to 2.1 times more likely than white children to be diagnosed with AD, more than twice as likely to have severe disease, and more than three times as likely to have persistent AD into later childhood (Croce, Wang, and Lipoff, JACI, 2021, PMC8578465).

Why it gets missed. Image audits of dermatology textbooks repeatedly find that 4 to 18 percent of clinical photographs depict darker skin (Adelekun, Onyekaba, and Lipoff; Louie and Wilkes; reviewed by Lester, PubMed 31157429). Medical students and residents are trained on a near-monochrome image set, then apply that pattern to every patient.

Symptoms

  • Itch first, often before any visible lesion. Severe itch that disrupts sleep is the most reliable symptom across skin tones.
  • Dry, scaly skin with poorly defined borders, often on the cheeks and scalp in infants, the flexures (inner elbows, behind the knees) in children, and the hands, eyelids, and neck in adults.
  • Papular eczema: small 1 to 2 mm bumps clustered on the trunk and extensors, often without the classic plaques.
  • Follicular accentuation: bumpy texture that follows hair follicles, especially on the chest, back, and abdomen.
  • Lichenification: thickened, leathery skin with exaggerated skin lines from chronic rubbing.
  • Post-inflammatory hyperpigmentation or hypopigmentation that outlasts the active flare.
  • Periorbital darkening and infraorbital folds (Dennie-Morgan lines).
  • Sleep disruption, daytime fatigue, and concentration problems driven by nighttime itch.

When to see a doctor

See a clinician if itch is interfering with sleep, school, or work, if over-the-counter moisturizers and 1 percent hydrocortisone are not controlling flares, or if rash is spreading. Get same-day care for signs of infection: honey-colored crust, pus, fever, rapidly worsening pain, or punched-out erosions (eczema herpeticum is a dermatologic emergency, particularly in children, and presents as monomorphic vesicles or punched-out ulcers on top of eczema). If you have been told you have "sensitive skin" or "ashy skin" for years and nothing has helped, ask specifically to be evaluated for atopic dermatitis.

Screening

There is no population screening test for atopic dermatitis. Diagnosis is clinical. The strongest risk signal is a personal or family history of atopy: a parent or sibling with eczema, asthma, allergic rhinitis (hay fever), or food allergy. If a child has eczema, current allergy and dermatology guidance is that the threshold to evaluate for the rest of the atopic march, especially food allergy in infants with moderate-to-severe AD, should be low.

Treatment overview

The American Academy of Dermatology's 2023 guidelines for AD in adults (Sidbury et al., JAAD, 2023, PubMed 36641009) make strong recommendations for daily moisturizers, topical corticosteroids as first-line anti-inflammatory therapy, topical calcineurin inhibitors (tacrolimus, pimecrolimus), the PDE-4 inhibitor crisaborole, and the topical JAK inhibitor ruxolitinib cream for mild-to-moderate disease.

For moderate-to-severe disease that fails topicals, systemic options now include the biologics dupilumab and tralokinumab and the oral JAK inhibitors upadacitinib and abrocitinib. Dupilumab's phase 3 trials showed comparable efficacy across racial subgroups including Black/African American patients (Alexis et al., 2019). Despite that, real-world prescribing is unequal: a Florida pediatric cohort found Black children had odds ratio 0.43 of receiving dupilumab compared to non-Hispanic white peers (Jonsdottir et al., JACI Global, 2024, PMC11492344), and a national matched cohort study found Black adults with AD had significantly lower odds of being prescribed dupilumab within 12 months of treatment initiation (Al-Obaydi et al., JACI in Practice, 2023, PubMed 37225123).

For patients prone to recurrent skin infections (particularly Staphylococcus aureus colonization), the AAD conditionally recommends dilute bleach baths plus intranasal mupirocin. Wet-wrap therapy is conditionally recommended for flares. Antihistamines are not recommended as a primary treatment for itch in AD.

Questions to ask your doctor

Bring this list to your next appointment.

  1. Is my inflammation being scored accurately for my skin tone, or is the severity being underestimated because redness is harder to see?
  2. Which topical steroid potency is right for each area I am treating, and how long is safe to use it?
  3. Would a topical calcineurin inhibitor be a better fit for my face or skin folds to avoid pigmentation side effects?
  4. Am I a candidate for dupilumab, and what does my insurance require before approving it?
  5. How do I treat the dark spots (postinflammatory hyperpigmentation) that are left after flares resolve?
  6. Are there any Black dermatologists or skin-of-color clinics in my area who specialize in atopic dermatitis?

Find care for atopic dermatitis on black skin

Not sure where to start? Describe what you're experiencing and we'll help you find the right kind of care, including a dermatology.

Find care

The numbers

  • Black children have an atopic dermatitis prevalence of 19.3 percent, compared to 16.1 percent for white children and 7.8 percent for Hispanic children, based on National Health and Nutrition Examination Survey data.[3]
  • Black children face a sixfold greater risk of severe atopic dermatitis than white children.[2]
  • A 2025 scoping review covering 53 studies found that Black and Hispanic children had a 1.5 to 3.8 times higher odds of hospitalization or urgent care visits compared to white children with the same diagnosis.[2]
  • Black children with atopic dermatitis had nearly four times higher odds of experiencing harmful financial impact related to their condition (odds ratio 3.86) and 32 percent higher odds of food insecurity compared to white peers.[2]
  • Despite higher disease burden, Black children were less likely to receive certain atopic dermatitis treatments and reported longer wait times for initial appointments and diagnosis.[2]
  • Black and Hispanic patients with atopic dermatitis report 1.8 to 2.3 times higher annual healthcare expenditures than white patients with the same condition.[2]

What it is

Atopic dermatitis is a chronic inflammatory skin disease driven by a breakdown in the skin barrier combined with an overactive immune response. Disruption in skin proteins -- particularly filaggrin -- allows moisture to escape and allergens and irritants to enter, triggering immune activation and the itch-scratch cycle that defines the condition. It is not contagious, and it is not caused by poor hygiene. Atopic dermatitis is the most common chronic skin disease in children, and it often coexists with asthma and allergic rhinitis in a pattern called the atopic march. Flares are typically triggered by dry skin, sweat, heat, certain fabrics, fragrances, and stress. There is no cure, but with the right regimen the condition is manageable and remission is achievable.

Sources: American Academy of Dermatology (AAD),[4] PMC (NIH).[3]

How it looks in Black skin

This is the section most clinical resources skip, and it is the section that matters most for accurate diagnosis.

In lighter skin, atopic dermatitis typically presents as red, weeping patches in the creases of elbows and knees. In Black skin, the same disease looks different in three important ways:

Color. Inflammation in darker skin does not appear red. It appears violaceous (purplish-brown), ashen gray, or a darker shade of brown. In 2023, a joint AAD and American Academy of Allergy, Asthma and Immunology task force updated the clinical definition of erythema in atopic dermatitis to explicitly include these darker-tone variants -- an acknowledgment that the old red-only definition excluded most Black patients.[5]

Morphology. Black patients show a stronger tendency toward papular or perifollicular presentation: clusters of small, discrete papules 1 to 2 mm in size rather than confluent patches. Extensor surfaces (outside of elbows and knees, the trunk, shins) are involved more often than in white patients, and lichenification (thickened, leathery skin from repeated scratching) is more pronounced.[3][5]

After the flare. Once inflammation resolves, Black skin is left with postinflammatory hyperpigmentation (PIH): dark spots that can persist for months and are often as distressing as the active rash. PIH is not a sign the rash is still active, but it is a real and lasting consequence of inadequately controlled disease that lighter-skinned patients rarely face to the same degree.[3]

Because erythema is harder to see in darker skin, clinicians can underestimate severity or dismiss active disease as residual PIH -- a pattern that delays treatment and allows disease to worsen.[5]

Treatment, plainly

Atopic dermatitis is a ladder: you start at the bottom and escalate when the current step does not control the disease.

Step 1: Skin barrier repair. Daily thick emollient (not lotion -- cream or ointment) applied within three minutes of bathing. This is the non-negotiable foundation of every treatment plan. Petroleum jelly is inexpensive and highly effective.

Step 2: Topical corticosteroids for flares. Low-potency (hydrocortisone 1-2.5%) for the face and skin folds. Medium potency (triamcinolone 0.1%, fluocinolone 0.025%) for the body. High potency (clobetasol 0.05%) reserved for short courses on thick-skinned areas. In Black patients, a specific caution: prolonged use of high-potency corticosteroids on the face or sensitive areas carries risk of hypopigmentation -- lightening of the skin around the treated area -- which is more visible and more distressing in darker skin tones. Use the lowest effective potency for the shortest effective duration.[6]

Step 3: Topical calcineurin inhibitors (TCIs). Tacrolimus ointment (0.03% for children, 0.1% for adults) and pimecrolimus cream 1% are approved for patients 2 and older. They do not cause skin thinning or pigmentation changes, making them a preferred option for the face, eyelids, and skin folds in Black patients where steroid side effects are a greater concern.[3]

Step 4: Topical JAK inhibitor. Ruxolitinib 1.5% cream (Opzelura) is FDA-approved for mild-to-moderate atopic dermatitis in patients 12 and older with inadequate response to topical steroids. The AAD guidelines strongly recommend topical JAK inhibitors with moderate certainty of evidence; the joint AAD/AAAAI task force guidelines express more caution about safety signals in the drug class generally. Discuss with your dermatologist.[7]

Step 5: Systemic biologics and JAK inhibitors. For moderate-to-severe disease: - Dupilumab (Dupixent): anti-IL-4/IL-13 biologic, FDA-approved for ages 6 months and older, injected every two to four weeks. Strong efficacy and safety data; no laboratory monitoring required.[7] - Tralokinumab (Adbry): anti-IL-13 biologic, approved for adults with moderate-to-severe AD. - Oral JAK inhibitors -- abrocitinib (Cibinqo) and upadacitinib (Rinvoq) -- are FDA-approved for adults with moderate-to-severe AD with inadequate response to other treatments. The AAD strongly recommends both; note that the drug class carries a labeling warning for increased infection risk, serious cardiovascular events, and malignancy (largely derived from rheumatoid arthritis populations at higher doses).[7]

How to find care

Sources

  1. American Academy of Dermatology. "Eczema types: atopic dermatitis overview." https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis
  2. Gottlieb A, et al. "An Updated Scoping Review of Disparities in Pediatric Atopic Dermatitis." Pediatric Dermatology. 2025. PMC12118532. https://pmc.ncbi.nlm.nih.gov/articles/PMC12118532/
  3. Heath CR, et al. "Dermatological Conditions in Skin of Color: Managing Atopic Dermatitis." Journal of Clinical and Aesthetic Dermatology. 2021. PMC8211323. https://pmc.ncbi.nlm.nih.gov/articles/PMC8211323/
  4. American Academy of Dermatology. "Atopic dermatitis: diagnosis, treatment, and outcome." https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/treatment
  5. Medscape. "How Does Atopic Dermatitis Present in Skin of Color?" Updated 2023. https://www.medscape.com/viewarticle/964651
  6. American Academy of Family Physicians. "Topical Corticosteroids: Choice and Application." American Family Physician. March 2021. https://www.aafp.org/pubs/afp/issues/2021/0315/p337.html
  7. American Journal of Managed Care. "Monoclonal Antibodies and JAK Inhibitors in Atopic Dermatitis Management: 2024 Guidelines and Managed Care Considerations." https://www.ajmc.com/view/monoclonal-antibodies-and-jak-inhibitors-in-atopic-dermatitis-management-2024-guidelines-and-managed-care-considerations
  8. Patient Care Online. "Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care Are Persistent and Significant: New Scoping Review." https://www.patientcareonline.com/view/health-disparities-in-pediatric-atopic-dermatitis-new-scoping-review-reveals-persistent-inequities

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Medical disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.

Share:
Find a Black doctor near you Start your consult